Topics

Articles

Delays could harm older Americans, interest group states.

AARP Advocates Timely Medicare Drug Price Negotiations

In what could presage a radical reshuffling of drug pricing and distribution, the insurer is dropping CVS Caremark as its PBM.

Blue Shield of California Bids to Sidestep Traditional Pharmacy Benefit Management Services 

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.

Illinois Governor Signs Legislation Targeting PBM Retaliation

Analysis requested by PhRMA indicates that these facilities charge anywhere from two to seven times what they originally paid. 

 Report: Hospitals Mark Up Medication Prices by 500%

Pharma Commerce team attends DIA's Annual Meeting for the first time.

The Voyage to Beantown

A dive into the issue of evidence gaps, plus the case for a chief access officer.

Are CEOs Getting Access Right?

While an option for financial assistance, patients should consider the challenges.

AFP Caution Flag for Patients

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Breaking the Pharma Industry’s Bundled Pricing Arrangements

Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

What’s Next for Biopharma Under the Inflation Reduction Act

Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.

Market Access and Pricing